Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Tarolli, Christopher G.a; b; * | Andrzejewski, Kellyc | Zimmerman, Grace A.a | Bull, Michaela | Goldenthal, Stevenb; d | Auinger, Peggyb | O’Brien, Michaele | Dorsey, E. Raya; b | Biglan, Kevinf | Simuni, Tanyag
Affiliations: [a] Department of Neurology, University of Rochester, Rochester, NY, USA | [b] Center for Health+Technology, University of Rochester, Rochester, NY | [c] Department of Neurology, University at Buffalo, Buffalo, NY, USA | [d] University of Michigan Medical School, Ann Arbor, MI, USA | [e] AMC Health, New York, NY, USA | [f] Early Phase Clinical Development, Eli Lilly and Company, Indianapolis, IN, USA | [g] Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Correspondence: [*] Correspondence to: Christopher G. Tarolli, MD, MS, 601 Elmwood Ave, Box MIND, Rochester, NY 14642, USA. Tel.: +1585 275 2427; Fax: +1 585 756 5189; E-mail: [email protected].
Abstract: Background:There is rising interest in remote clinical trial assessments, particularly in the setting of the COVID-19 pandemic. Objective:To demonstrate the feasibility, reliability, and value of remote visits in a phase III clinical trial of individuals with Parkinson’s disease. Methods:We invited individuals with Parkinson’s disease enrolled in a phase III clinical trial (STEADY-PD III) to enroll in a sub-study of remote video-based visits. Participants completed three remote visits over one year within four weeks of an in-person visit and completed assessments performed during the remote visit. We evaluated the ability to complete scheduled assessments remotely; agreement between remote and in-person outcome measures; and opinions of remote visits. Results:We enrolled 40 participants (mean (SD) age 64.3 (10.4), 29% women), and 38 (95%) completed all remote visits. There was excellent correlation (ICC 0.81–0.87) between remote and in-person patient-reported outcomes, and moderate correlation (ICC 0.43–0.51) between remote and in-person motor assessments. On average, remote visits took around one quarter of the time of in-person visits (54 vs 190 minutes). Nearly all participants liked remote visits, and three-quarters said they would be more likely to participate in future trials if some visits could be conducted remotely. Conclusion:Remote visits are feasible and reliable in a phase III clinical trial of individuals with early, untreated Parkinson’s disease. These visits are shorter, reduce participant burden, and enable safe conduct of research visits, which is especially important in the COVID-19 pandemic.
Keywords: Clinical trial protocol, Parkinson’s disease, phase III clinical trial, technology, telemedicine
DOI: 10.3233/JPD-202163
Journal: Journal of Parkinson's Disease, vol. 10, no. 4, pp. 1779-1786, 2020
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]